🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

13 results for “Ferring Pharmaceuticals” Clear

  1. ADSTILADRIN

    Ferring Pharmaceuticals

    Intermediate risk, non-muscle invasive bladder cancer

    phase 3 small molecule active

    1 trial

  2. Desmopressin

    Ferring Pharmaceuticals

    Nocturia

    phase 3 small molecule completed

    1 trial

  3. FE 999326

    Ferring Pharmaceuticals

    Bladder Cancer

    phase 3 small molecule active

    1 trial

  4. FE 999913 vaginal tablet

    Ferring Pharmaceuticals

    Luteal Hormone Supplementation

    phase 3 small molecule completed

    1 trial

  5. Follitropin alfa

    Ferring Pharmaceuticals

    Controlled Ovarian Simulation

    phase 3 small molecule completed

    1 trial

  6. KEYTRUDA 25 mg/mL concentrate for solution for infusion, ADSTILADRIN, GEMCITABINE , DOCETAXEL

    Ferring Pharmaceuticals

    High-risk Bacillus Calmette-Guerin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC) with carcinoma in situ(CIS) with or without papillary tumours

    phase 3 small molecule active

    1 trial

  7. ADSTILADRIN

    Ferring Pharmaceuticals

    Low-grade upper track urothelial carcinoma (LG-UTUC)

    phase 2 small molecule active

    1 trial

  8. Placebo comparator, intramuscular injection, TRI-001

    Ferring Pharmaceuticals

    Patients with Chronic Limb Threatening Ischemia (CLTI) due to Peripheral Arterial Disease (PAD)

    phase 2 small molecule active

    1 trial

  9. REKOVELLE 72 micrograms/2.16 mL solution for injection in a pre-filled pen, Pre-filled pen containing 2.16mL solution, subcutaneous injection

    Ferring Pharmaceuticals

    Idiopathic male infertility (including oligoasthenozoospermia).

    phase 2 small molecule active

    1 trial

  10. A study in healthy subjects investigating the safety, tolerability and concentrations of FE 999301 after single and multiple doses

    Ferring Pharmaceuticals

    Inflammatory Gastrointestinal Disease

    phase 1 other active

    1 trial

  11. An exploratory study to investigate the effect of FE 999302 when given during different time periods to women undergoing controlled ovarian stimulation with follitropin delta

    Ferring Pharmaceuticals

    Infertility in women undergoing assisted reproductive technologies (ART)

    phase 1 other active

    1 trial

  12. An exploratory study to investigate the effect of FE 999302 when given together with follitropin delta during controlled ovarian stimulation

    Ferring Pharmaceuticals

    Infertility in women undergoing assisted reproductive technologies (ART)

    phase 1 other active

    1 trial

  13. Budesonide

    Ferring Pharmaceuticals

    Healthy

    phase 1 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources